Indium (In-111) Chloride Curiumpharma

What Is Indium (In-111) Chloride and What Is It Used For?

Indium (In-111) chloride is a sterile, carrier-free radioactive solution used exclusively as a radiolabeling agent in nuclear medicine. It is used to tag white blood cells, platelets, monoclonal antibodies, and peptides with the radioactive isotope Indium-111, enabling physicians to visualize infections, inflammation, and tumors using SPECT (Single Photon Emission Computed Tomography) imaging.

Indium (In-111) chloride is a diagnostic radiopharmaceutical precursor manufactured by Curium Pharma (formerly known under brands such as Indiclor by GE Healthcare). Unlike most medications, it is never administered directly to patients in its native form. Instead, it serves as the radioactive component in a multi-step laboratory procedure where biological materials such as white blood cells or monoclonal antibodies are labeled with the radioactive tracer before being reintroduced into the patient for diagnostic imaging purposes.

The active substance is indium-111, a synthetic radioisotope that decays by electron capture with a physical half-life of 2.8 days (67.3 hours). During this decay process, it emits two principal gamma photons at energies of 171.3 keV (91% abundance) and 245.4 keV (94% abundance). These energy levels are ideally suited for detection by modern gamma cameras and SPECT scanners, producing high-quality diagnostic images that help clinicians identify the location and extent of pathological processes within the body.

The product is supplied as a clear, colorless, sterile solution of indium-111 chloride in dilute hydrochloric acid (0.05 M, pH 1.1-1.4). Each vial typically contains 185 MBq (5 mCi) of activity at the time of calibration, with a specific activity exceeding 1.85 GBq per microgram, confirming its carrier-free status. This high specific activity is essential for efficient radiolabeling of biological materials without introducing pharmacologically significant quantities of non-radioactive indium.

Primary Clinical Applications

The most important clinical application of Indium (In-111) chloride is the preparation of In-111 labeled white blood cells (leukocytes) for infection and inflammation imaging. In this procedure, a blood sample is drawn from the patient, the white blood cells are isolated through differential centrifugation, labeled with In-111 via an oxine chelator, and then reinjected intravenously. The labeled white blood cells naturally migrate to sites of active infection or inflammation, where they accumulate and can be detected by gamma camera imaging.

This technique is particularly valuable for detecting and localizing occult infections that are difficult to identify with conventional imaging methods such as X-ray, CT, or MRI. Common clinical indications include suspected osteomyelitis in the extremities, prosthetic joint infections, vascular graft infections, intra-abdominal abscesses, diabetic foot infections, and fever of unknown origin. The sensitivity of In-111 white blood cell scintigraphy ranges from 74% to 92%, with specificity of 68% to 92%, making it one of the most reliable nuclear medicine techniques for infection imaging.

Beyond white blood cell labeling, Indium (In-111) chloride is also used to radiolabel monoclonal antibodies for tumor imaging (immunoscintigraphy), platelets for thrombus detection and platelet kinetics studies, and peptides such as pentetreotide for somatostatin receptor scintigraphy in neuroendocrine tumors. These diverse applications make it one of the most versatile radiolabeling agents in nuclear medicine practice.

What Should You Know Before Using Indium (In-111) Chloride?

Indium (In-111) chloride is handled exclusively by nuclear medicine professionals. It is contraindicated in pregnancy due to ionizing radiation risks, and breastfeeding should be interrupted after procedures using In-111 labeled products. Patients with severe leukopenia may not be suitable candidates for white blood cell labeling studies.

Because Indium (In-111) chloride is a radioactive material used only within nuclear medicine departments, safety considerations apply both to the healthcare professionals handling the product and to the patients who receive the final labeled preparations. All handling must comply with national radiation protection regulations and follow the ALARA principle (As Low As Reasonably Achievable), which mandates that radiation exposure to both staff and patients should be minimized to the lowest practical level consistent with obtaining adequate diagnostic information.

Contraindications

The primary absolute contraindication for procedures involving Indium-111 labeled products is pregnancy. Ionizing radiation from any source, including diagnostic radiopharmaceuticals, has the potential to cause harm to the developing fetus, including teratogenic effects and an increased lifetime risk of childhood cancer. Before any nuclear medicine procedure involving In-111, women of childbearing potential must be asked about the possibility of pregnancy, and a pregnancy test may be required in cases of uncertainty.

In emergency situations where an In-111 labeled study is deemed essential for a pregnant patient, the potential benefits must be carefully weighed against the radiation risks to the fetus, and this decision should be made by a senior nuclear medicine physician in consultation with the referring clinician and the patient. The estimated fetal dose from an In-111 white blood cell scan is approximately 3-5 mGy, which is above the threshold that warrants careful consideration but below the level associated with deterministic effects.

Warnings and Precautions

Several important precautions apply to the use of Indium (In-111) chloride and its labeled products:

• Radiation exposure: The effective dose from an In-111 white blood cell scan is approximately 6-12 mSv, which is higher than many other nuclear medicine procedures. This must be considered in the context of cumulative radiation exposure, particularly in patients requiring repeated studies
• Handling requirements: Indium-111 chloride must be handled only by personnel who are qualified and authorized to handle radioactive materials. Appropriate shielding (lead containers, syringe shields) must be used at all times
• Quality control: The radiolabeling efficiency of white blood cells should be verified before administration, with a minimum acceptable labeling efficiency typically set at 50%. Poor labeling efficiency can result in suboptimal image quality and potential misdiagnosis
• Cell viability: The labeling process must not compromise the viability and function of the white blood cells, as damaged cells will not migrate normally to infection sites and may accumulate in the lungs, leading to false-positive results
• Leukopenia: Patients with severe leukopenia (low white blood cell count) may not be suitable candidates for In-111 white blood cell scans, as insufficient cells may be available for effective labeling. Alternative imaging approaches should be considered in these patients

Pregnancy and Breastfeeding

As noted above, procedures involving Indium-111 labeled products are generally contraindicated during pregnancy. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both recommend that nuclear medicine procedures in pregnant women should only be performed when the expected clinical benefit outweighs the risk of radiation exposure to the fetus.

For breastfeeding mothers, it is recommended that breastfeeding be interrupted for a period following administration of In-111 labeled products. The International Commission on Radiological Protection (ICRP) recommends interrupting breastfeeding for at least 1 week after administration of In-111 labeled leukocytes to ensure that the infant's radiation dose from ingested breast milk is minimized. During this period, breast milk should be expressed and discarded to maintain lactation. The specific duration of interruption may vary based on institutional protocols and the specific labeled product used.

How Does Indium (In-111) Chloride Interact with Other Drugs?

While Indium (In-111) chloride itself does not have traditional pharmacological drug interactions, several medications can interfere with the diagnostic accuracy of In-111 labeled white blood cell scans by altering white blood cell distribution, function, or migration patterns. These include corticosteroids, antibiotics, and immunosuppressive agents.

Unlike conventional medications that interact through metabolic pathways or receptor binding, the interactions relevant to Indium (In-111) chloride are primarily diagnostic in nature. Certain drugs can affect the quality and accuracy of the diagnostic images obtained after administration of In-111 labeled products, potentially leading to false-positive or false-negative results. Understanding these interactions is essential for nuclear medicine physicians to correctly interpret scan findings and for referring clinicians to appropriately time imaging studies.

The most clinically significant interactions involve medications that affect white blood cell count, function, or migration patterns, as these directly impact the sensitivity and specificity of In-111 labeled leukocyte imaging. Additionally, any medication that suppresses the inflammatory response may reduce the accumulation of labeled white blood cells at infection sites, potentially masking clinically significant infections.

Major Interactions

The most clinically significant interactions involve corticosteroids and immunosuppressive medications. High-dose corticosteroid therapy can dramatically reduce the sensitivity of In-111 white blood cell scans by suppressing the normal inflammatory cascade that drives white blood cell migration to infection sites. In patients receiving chronic corticosteroid therapy, the scan may appear falsely negative even in the presence of active infection. Nuclear medicine physicians must be aware of concurrent steroid therapy when interpreting scan results, and referring clinicians should communicate this information when requesting the study.

Similarly, immunosuppressive agents used in transplant recipients and autoimmune disease patients can impair both the quantity and function of white blood cells, reducing the diagnostic utility of In-111 labeled leukocyte imaging. In severely immunosuppressed patients, alternative imaging modalities such as FDG-PET/CT may provide better diagnostic accuracy for infection detection.

Minor Interactions

Non-steroidal anti-inflammatory drugs (NSAIDs) have a theoretical potential to reduce inflammatory cell accumulation at infection sites, but the clinical impact on In-111 white blood cell scan accuracy is generally minimal. Most nuclear medicine departments do not require patients to discontinue NSAIDs before undergoing In-111 labeled studies. Anticoagulant medications have minimal impact on white blood cell labeling but may significantly affect platelet labeling studies, where accurate platelet function is essential for proper tracer distribution.

What Is the Correct Dosage of Indium (In-111) Chloride?

The dosage of Indium (In-111) chloride refers to the radioactivity used for labeling, not a conventional drug dose. For adult white blood cell scans, 10-20 MBq (0.27-0.54 mCi) of In-111 labeled leukocytes is typically administered intravenously. Pediatric doses are calculated based on body weight at 0.15-0.25 MBq/kg. All dosing is determined and administered exclusively by nuclear medicine professionals.

Understanding the dosage of Indium (In-111) chloride requires an important conceptual distinction from conventional medication dosing. In nuclear medicine, the "dose" refers to the amount of radioactivity (measured in megabecquerels or millicuries) rather than a mass of active pharmaceutical ingredient. The objective is to administer the minimum radioactivity necessary to obtain diagnostic-quality images while keeping radiation exposure as low as reasonably achievable (ALARA principle).

The Indium (In-111) chloride vial itself typically contains 185 MBq (5 mCi) of activity at calibration. However, not all of this radioactivity is administered to the patient. The actual patient dose depends on the labeling efficiency (typically 50-80% for white blood cell labeling), the specific clinical application, the patient's body weight, and institutional protocols. The nuclear medicine physician prescribes the appropriate activity based on current guidelines from organizations such as the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Adults

For adult white blood cell scintigraphy, the standard administered activity is 10-20 MBq (0.27-0.54 mCi) of In-111 labeled leukocytes. This activity level provides adequate count rates for diagnostic-quality SPECT imaging while keeping the patient's effective radiation dose within acceptable limits. The European Association of Nuclear Medicine (EANM) recommends an administered activity of 10-18.5 MBq for routine infection imaging in adults.

Imaging is typically performed at two time points: an early scan at 1-4 hours post-injection and a delayed scan at 16-30 hours post-injection. The early scan establishes a baseline distribution of labeled cells, while the delayed scan allows sufficient time for white blood cells to migrate to and accumulate at infection sites. In some clinical scenarios, additional imaging at 48 hours may be performed to differentiate between infection and sterile inflammation.

Children

Pediatric dosing of In-111 labeled leukocytes follows weight-based calculations, with the administered activity typically ranging from 0.15 to 0.25 MBq per kilogram of body weight. The minimum administered activity for any pediatric patient should not be less than 2 MBq to ensure adequate image quality. The EANM Paediatric Committee has published detailed dosage cards that provide age- and weight-specific recommendations for pediatric nuclear medicine procedures, including In-111 labeled studies.

Due to the relatively high radiation dose associated with In-111 compared to technetium-99m (Tc-99m) alternatives, the use of In-111 labeled white blood cell scans in children requires careful justification. In many pediatric centers, Tc-99m HMPAO-labeled leukocytes are preferred due to the lower radiation burden, unless specific clinical circumstances favor the use of In-111 (such as the need for delayed imaging or evaluation of abdominal infections where bowel excretion of Tc-99m HMPAO may confound interpretation).

Elderly

No specific dose adjustment is required for elderly patients. The same administered activity range of 10-20 MBq applies as for younger adults. However, in elderly patients with multiple comorbidities, the nuclear medicine physician should consider the cumulative radiation exposure from previous imaging studies and the patient's overall prognosis when determining the appropriateness of the examination. Additionally, elderly patients may have reduced bone marrow reserve or chronic medications that could affect white blood cell count and function, potentially impacting labeling efficiency and scan quality.

Missed Dose

The concept of a "missed dose" does not apply to Indium (In-111) chloride in the same way it applies to conventional medications. Since the product is used for a single diagnostic procedure rather than ongoing therapy, there is no dosing schedule to maintain. If a scheduled imaging study is postponed or cancelled after the blood sample has been drawn and labeled, the labeled cells cannot be stored for later use due to radioactive decay and loss of cell viability. A new blood draw and labeling procedure would be required for a rescheduled study.

Overdose

Overdose with Indium (In-111) labeled products results in unnecessary radiation exposure to the patient. In the event of accidental administration of a significantly higher activity than intended, the nuclear medicine physician should estimate the additional radiation dose to the patient and document the incident according to institutional radiation safety protocols. There is no specific antidote for radiation overexposure from In-111. The radioactive decay is a physical process that cannot be accelerated. Adequate hydration may help promote urinary excretion of any unbound In-111, and the patient should be monitored as clinically appropriate. National radiation safety authorities should be notified if the overexposure exceeds reporting thresholds.

What Are the Side Effects of Indium (In-111) Chloride?

Side effects from Indium-111 labeled diagnostic procedures are generally minimal since the product is used in trace diagnostic amounts. The primary safety consideration is radiation exposure, with an effective dose of approximately 6-12 mSv for white blood cell scans. Rare allergic reactions (urticaria) have been reported. The target organs for radiation dose are the spleen, liver, and bone marrow.

Indium (In-111) chloride has an excellent safety profile for a diagnostic radiopharmaceutical. Because the labeled products are administered in trace quantities without pharmacological activity, conventional drug side effects (such as gastrointestinal symptoms, headaches, or metabolic disturbances) are virtually absent. The safety considerations are primarily related to the ionizing radiation inherent in any nuclear medicine procedure, and to rare hypersensitivity reactions to the labeled preparation.

It is important for patients to understand that the radiation dose from an In-111 labeled study, while not negligible, is within the range accepted for diagnostic medical procedures and is carefully weighed against the clinical benefit of the information obtained. The following classification of potential adverse effects follows the standard frequency categories used by the European Medicines Agency (EMA).

The radiation dose to specific organs from an In-111 white blood cell scan varies depending on the distribution of labeled cells within the body. The spleen typically receives the highest absorbed dose (approximately 60-90 mGy), as it is the primary site of white blood cell sequestration. The liver receives approximately 10-20 mGy, and the bone marrow receives approximately 5-15 mGy. These organ doses are generally well within accepted safety limits for diagnostic nuclear medicine procedures.

Children are more radiosensitive than adults, meaning that the same radiation dose carries a proportionally higher risk of stochastic effects (such as radiation-induced cancer) in pediatric patients. For this reason, the use of In-111 labeled studies in children requires particularly careful justification, and the administered activity should be minimized to the lowest level consistent with obtaining diagnostic-quality images. Many pediatric nuclear medicine centers prefer Tc-99m labeled alternatives when clinically appropriate, as they deliver a significantly lower radiation dose (0.7-1.0 mSv compared to 6-12 mSv for In-111).

How Should Indium (In-111) Chloride Be Stored?

Indium (In-111) chloride must be stored at controlled room temperature (20-25°C / 68-77°F) within its transportation shield in a designated radioactive materials storage area. It must be handled using forceps and appropriate shielding. Storage and disposal must comply with national radiation safety regulations.

The storage of Indium (In-111) chloride involves both standard pharmaceutical storage conditions and specific requirements related to its radioactive nature. As a radioactive material, it is subject to strict regulatory control from the point of manufacture through to final disposal, and all storage facilities must be licensed by the relevant national radiation safety authority.

The product should be stored at controlled room temperature of 20-25 degrees Celsius (68-77 degrees Fahrenheit). It must be kept within its lead transportation shield at all times to minimize radiation exposure to personnel and the environment. The vial should never be removed from the shield except when actively dispensing the product, and forceps should be used for handling to maximize the distance between the radioactive source and the operator's hands.

Due to the 67.3-hour half-life of Indium-111, the product has a limited usable shelf life. The radioactivity decreases by approximately 50% every 2.8 days, and the product should be used within the period specified on the label (typically within a few days of calibration) to ensure that sufficient radioactivity is available for effective radiolabeling. After the expiration date or once the remaining radioactivity is insufficient for clinical use, the product must be disposed of as radioactive waste in accordance with institutional and regulatory protocols.

The shielding properties of lead against Indium-111 gamma radiation are well characterized: the first half-value layer of lead is 0.023 cm, and approximately 0.834 cm of lead decreases the external radiation exposure by a factor of 1,000. Nuclear medicine departments typically use dedicated lead-lined storage cabinets or hot labs for storing radiopharmaceuticals, with appropriate signage indicating the presence of radioactive materials.

What Does Indium (In-111) Chloride Contain?

Indium (In-111) chloride solution contains carrier-free indium-111 chloride (InCl3) dissolved in 0.05 M hydrochloric acid (pH 1.1-1.4). The solution is sterile and non-pyrogenic, with no added preservatives or stabilizers. Each vial typically contains 0.5 mL of solution with 185 MBq (5 mCi) of radioactivity at calibration.

The composition of Indium (In-111) chloride is notably simple compared to most pharmaceutical products. The active substance is indium-111 in the form of its chloride salt (InCl3), dissolved in a dilute hydrochloric acid solution. The carrier-free designation means that the solution contains no added non-radioactive (stable) indium, resulting in a very high specific activity that is essential for efficient radiolabeling of biological materials.

Active Ingredient

The active ingredient is Indium-111 chloride (111InCl3), a radioactive isotope of indium. Indium-111 is produced artificially by cyclotron irradiation of enriched cadmium targets, primarily via the nuclear reaction 112Cd(p,2n)111In, where cadmium-112 is bombarded with protons in a particle accelerator. The resulting indium-111 is then chemically separated and purified to produce a carrier-free chloride solution of high radionuclide purity.

The radionuclide purity specifications require that In-111 constitutes at least 99.9% of the total radioactivity at calibration, with no more than 0.1% attributable to other radioactive contaminants such as indium-114m. This high purity is essential to ensure accurate dosimetry and optimal image quality.

Inactive Ingredients

• Hydrochloric acid (0.05 M): Serves as the solvent and maintains the acidic pH (1.1-1.4) necessary to keep indium-111 chloride in solution and prevent hydrolysis
• Water for injection: Pharmaceutical-grade water used as the primary diluent

No preservatives, stabilizers, buffers, or other excipients are added to the formulation. The solution is sterilized by filtration through a 0.22-micrometer membrane filter and is tested for sterility and bacterial endotoxin content before release. The simple formulation minimizes the risk of chemical interference with the radiolabeling process and reduces the potential for adverse reactions in patients who ultimately receive the labeled products.

Physical Properties

Frequently Asked Questions